Information was received from a healthcare provider (hcp) regarding a trial patient who was using an external neurostimulator (ens) for non-obstructive urinary retention.It was noted that the patient¿s trial started on (b)(6) 2023.It was reported that the patient (pt) became light-headed and dizzy the night of the procedure.They fell on their backside, right where the trial procedure was done.They went to the hospital and were treated for pain in that area.They were discharged the following day, but continued to have pain.They were readmitted to the hospital on(b)(6) 2023 with pain in the same area.The pain was across the lower back where the procedure stage 1 as performed.The patient had a lidocaine patch on that area and were still in pain.The hcp made the decision to remove the device and cancel the trial.Stage 1 was removed without complication.The patient will most likely not have another trial.
|
Concomitant medical products: product id: 978b128, lot# va2njjp, implanted: (b)(6) 2023, explanted: (b)(6) 2023, product type: lead.Other relevant device(s) are: product id: 978b128, serial/lot #: va2njjp, ubd: 03-mar-2024, udi#: (b)(4).Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|